VBI-002

VBI-002 is a novel bispecific monoclonal antibody developed by Virtuoso Therapeutics that targets both CD47 and intercellular adhesion molecule 1 (ICAM-1). The drug is designed to selectively block the interaction between CD47 and SIRPα on tumor cells with high ICAM-1 expression. This dual targeting enhances tumor selectivity and reduces off-tumor toxicity compared to monospecific anti-CD47 antibodies. VBI-002 features a human IgG1 Fc region engineered for full effector function using knobs-in-holes technology. Preclinical studies demonstrate potent single-agent antitumor activity in various solid tumor models—including non-small cell lung cancer (NSCLC), hepatocellular carcinoma, and melanoma—as well as synergy with standard chemotherapies such as paclitaxel and irinotecan. The mechanism of action includes blockade of the "don't eat me" signal via CD47 inhibition, direct cytotoxicity through ADCC (antibody-dependent cell-mediated cytotoxicity) and ADCP (antibody-dependent cellular phagocytosis), specifically in tumors co-expressing high levels of both targets[1][2][4]. Safety studies in non-human primates indicate good tolerability at clinically relevant doses.

Other names

CD47 x ICAM-1 bispecific antibodyCD-47 x ICAM-1 bispecific antibodyCD 47 x ICAM-1 bispecific antibody